Friday, January 28, 2022
12:30PM – 1:30PM ET
Please note this TeleECHO program is 12:30PM Eastern, 11:30AM Central, 10:30AM Mountain and 9:30AM Pacific.
This series of TeleECHO activities will discuss the management of patients with advanced and/or metastatic (m) renal cell carcinoma (RCC) and therapeutic options available in the first-line setting.
Daniel M. Geynisman, MD
Associate Professor, Hematology/Oncology
Fox Chase Cancer Center
After completing the CME activity, learners should be better able to:
- Evaluate evidence from clinical trials assessing novel combination IO/TKI therapies for the treatment of patients with advanced and/or mRCC in the first-line setting
- Select patients with advanced and/or mRCC that are most likely to benefit from IO/TKI combination therapies in the first-line setting
- Devise strategies to manage the irAEs and trAEs associated IO/TKI combination therapies used in the first-line setting for patients with advanced and/or mRCC
This activity is intended for US-based community oncologists involved in the management of patients with RCC.
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the care of patients with advanced and/or metastatic RCC.
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at [email protected].
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]